Collegium Pharmaceutical ( (COLL) ) has shared an announcement.
Vikram Karnani has been appointed as the new CEO of Collegium Pharmaceutical, effective November 12, 2024, succeeding Michael Heffernan, who continues as Chairman. Karnani brings extensive experience from Amgen and Horizon Therapeutics, positioning Collegium for its next growth phase following the acquisition of Ironshore Therapeutics. Under his leadership, the company aims to capitalize on record revenues and expand its presence in neurology with Jornay PM® as a key growth driver.
For detailed information about COLL stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- Paramount Global (NASDAQ:PARA) Adds an Ad-Supported Tier in Europe
- How Ford (NYSE:F) Looks to Solve Its Hydrogen Engine Problem
- The Intel (NASDAQ:INTC) “Coffee Debacle” Is Now Solved
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
